Oniria Therapeutics develops novel cancer treatments focused on overcoming therapy resistance by targeting persistent, dormant tumor cells. The company's strategy modulates the dormant state of cancer cells to exploit inherent vulnerabilities, aiming to eliminate residual disease and improve patient outcomes. Their flagship molecule, ONR-001, allosterically activates the epigenetic enzyme TET2 to induce dormancy or cell death across various disease stages.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients develop resistance to existing therapies, leading to recurrence and metastasis, even after years of successful initial treatment. Cancer cells can evade drug therapies by entering a dormant state, allowing them to persist indefinitely within the body. This dormancy makes the cancer cells undetectable and allows them to return more aggressively.
Solution
ONIRIA Therapeutics is developing treatments that target cancer cell resistance by modulating the dormant state of tumor cells. Their approach exploits vulnerabilities that arise from dormancy, overcoming disease persistence and potentially prolonging patient survival. ONR-001, their lead molecule, allosterically activates TET2, a master epigenetic enzyme, inducing tumor cells to enter dormancy and even die. This method can be applied across all stages of the disease, from primary tumors to recurrent, resistant metastatic cancers.
Target Audience
The primary target audience includes cancer patients across all stages of the disease, from naïve primary tumors to recurrent resistant metastatic cancer, and the oncologists treating them.
Features
- ONR-001: A first-in-class molecule that allosterically activates TET2
- Induces tumor cell dormancy and cell death by modulating epigenetic activity
- Potential application across all stages of cancer, including naïve primary tumors and recurrent resistant metastatic cancer
- Exploits vulnerabilities of dormant cancer cells to overcome drug resistance